Provectus Biopharmaceuticals, Inc. (PVCT) stock
PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05+0.00 (+0.39%)
Close on Oct 19, 2026Market cap $20.55MP/E –Yield –
Provectus Biopharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Provectus Biopharmaceuticals's revenue for the twelve months ending Dec 31, 2025 was $336.11K, down 45.5% year over year. For fiscal 2025 it was $336.11K, down 45.5% from the year before. The highest annual figure on record is $989.04K in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $336.11K | -45.5% |
| FY2024 | Dec 31, 2024 | $617.14K | +10.7% |
| FY2023 | Dec 31, 2023 | $557.71K | -43.6% |
| FY2022 | Dec 31, 2022 | $989.04K | – |
| FY2015 | Dec 31, 2015 | $0 | – |
| FY2014 | Dec 31, 2014 | $0 | – |
| FY2013 | Dec 31, 2013 | $0 | – |
| FY2012 | Dec 31, 2012 | $0 | – |
| FY2011 | Dec 31, 2011 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $57.48K | -77.5% |
| Q1 FY2025 | Mar 31, 2025 | $278.63K | +17.0% |
| Q4 FY2024 | Dec 31, 2024 | $14.33K | -88.2% |
| Q3 FY2024 | Sep 30, 2024 | $109.75K | +57.4% |
| Q2 FY2024 | Jun 30, 2024 | $254.99K | +57.6% |
| Q1 FY2024 | Mar 31, 2024 | $238.07K | +16.1% |
| Q4 FY2023 | Dec 31, 2023 | $121.11K | -26.5% |
| Q3 FY2023 | Sep 30, 2023 | $69.73K | -77.9% |
| Q2 FY2023 | Jun 30, 2023 | $161.84K | -49.7% |
| Q1 FY2023 | Mar 31, 2023 | $205.03K | +9.3% |
| Q4 FY2022 | Dec 31, 2022 | $164.84K | – |
| Q3 FY2022 | Sep 30, 2022 | $314.89K | – |
| Q2 FY2022 | Jun 30, 2022 | $321.71K | – |
| Q1 FY2022 | Mar 31, 2022 | $187.61K | – |
| Q3 FY2016 | Sep 30, 2016 | $0 | – |
See a number that looks wrong?